Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson neuroscience Therapeutic Area Total — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, FY2025
7,837
Period ended Dec 28, 2025
Change on a year earlier
+10.1%
7,115 in FY2024
History
10 years
Since FY2016
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Neuroscience Therapeutic Area Total — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 7,837 | +10.1% | Form 10-K (filed 2026-02-11) ↗ |
| FY2024 | Dec 29, 2024 | 7,115 | -0.4% | Form 10-K (filed 2026-02-11) ↗ |
| FY2023 | Dec 31, 2023 | 7,140 | +3.6% | Form 10-K (filed 2026-02-11) ↗ |
| FY2022 | Jan 1, 2023 | 6,893 | -1.4% | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Jan 2, 2022 | 6,988 | +7.1% | Form 10-K (filed 2024-02-16) ↗ |
| FY2020 | Jan 3, 2021 | 6,526 | +3.1% | Form 10-K (filed 2023-02-16) ↗ |
| FY2019 | Dec 29, 2019 | 6,328 | +4.1% | Form 10-K (filed 2022-02-17) ↗ |
| FY2018 | Dec 30, 2018 | 6,077 | +1.5% | Form 10-K (filed 2021-02-22) ↗ |
| FY2017 | Dec 31, 2017 | 5,986 | -1.6% | Form 10-K (filed 2019-02-20) ↗ |
| FY2016 | Jan 1, 2017 | 6,085 | – | Form 10-K (filed 2019-02-20) ↗ |
Breakdown
What makes up neuroscience therapeutic area total — worldwide sales ($m)
- Neuroscience Therapeutic Area Total — U.S. sales ($M)5,151 · FY2025
- Neuroscience Therapeutic Area Total — International sales ($M)2,686 · FY2025
- Neuroscience Therapeutic Area Total — Worldwide reported growth YoY (%)10.1% · FY2025
- Neuroscience Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)9.9% · FY2025
- INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — Worldwide sales ($M)3,810 · FY2025
- SPRAVATO (esketamine) — Worldwide sales ($M)1,696 · FY2025
- CAPLYTA (lumateperone) — Worldwide sales ($M)700 · FY2025
- CONCERTA / methylphenidate — Worldwide sales ($M)584 · FY2025
- RISPERDAL CONSTA (risperidone) [reported separately through FY2022Q4] — Worldwide sales ($M)689 · FY2023
- Other Neuroscience medicines — Worldwide sales ($M)1,048 · FY2025
Cite this data
StockData. (2026). Johnson & Johnson Neuroscience Therapeutic Area Total — Worldwide sales ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/ta_neuroscience
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.